Joseph M Backer

US Patent:

7700557, Apr 20, 2010

Filed:

Aug 14, 2007

Appl. No.:

11/891863

Inventors:

Marina V. Backer - Simsbury CT, US
Joseph M. Backer - Simsbury CT, US

Assignee:

SibTech, Inc. - Brookfield CT

International Classification:

A61K 38/18
C07K 14/475

US Classification:

514 12, 530399, 530402

Abstract:

The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient.

US Patent:

7807778, Oct 5, 2010

Filed:

Mar 14, 2008

Appl. No.:

12/075811

Inventors:

Marina V. Backer - Simsbury CT, US
Joseph M. Backer - Simsbury CT, US

Assignee:

SibTech, Inc. - Brookfield CT

International Classification:

A61K 38/10
A61K 38/18
C07K 7/08
C07K 14/475

US Classification:

530300, 530326, 530399, 530402

Abstract:

The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety bound to the targeting moiety; the biological conjugate having a covalent bond between the thiol group of SEQ ID NO:2 and a functional group in the binding moiety. The present invention is directed to a biological conjugate, comprising: (a) a targeting moiety comprising a polypeptide having an amino acid sequence comprising the polypeptide sequence of SEQ ID NO:2 and the polypeptide sequence of a selected targeting protein; and (b) a binding moiety that comprises an adapter protein, the adapter protein having a thiol group; the biological conjugate having a disulfide bond between the thiol group of SEQ ID NO:2 and the thiol group of the adapter protein. The present invention is also directed to biological sequences employed in the above biological conjugates, as well as pharmaceutical preparations and methods using the above biological conjugates.

US Patent:

20100104550, Apr 29, 2010

Filed:

Aug 3, 2007

Appl. No.:

12/376021

Inventors:

Adrienne Webster Paton - South Australia, AU
James Cleland Paton - South Australia, AU
Marina V. Backer - Sandy Hook CT, US
Joseph M. Backer - Sandy Hook CT, US

Assignee:

ADELAIDE RESEARCH AND INNOVATION - Adelaide
SIBTECH, INC. - Newington CT

International Classification:

A61K 38/48
C12P 21/06
C12N 9/96
C07H 21/04

US Classification:

424 9464, 435 681, 435188, 536 232

Abstract:

Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention also relates to subtilase toxin molecules specifically targeting proliferating cells, in particular tumor cells, or cells expressing a vascular endothelial growth factor receptor.

US Patent:

55631304, Oct 8, 1996

Filed:

Dec 13, 1994

Appl. No.:

8/355371

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R. sub. 2 and R. sub. 3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

58439250, Dec 1, 1998

Filed:

Dec 13, 1994

Appl. No.:

8/354694

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 926

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R. sub. 2, R. sub. 3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

55676936, Oct 22, 1996

Filed:

Dec 13, 1994

Appl. No.:

8/354688

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 4700
A61K 926

US Classification:

514154

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C. sub. 1 -C. sub. 4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

58563156, Jan 5, 1999

Filed:

May 26, 1998

Appl. No.:

/084484

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 31025

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R. sub. 2, R. sub. 3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

54610290, Oct 24, 1995

Filed:

Apr 24, 1992

Appl. No.:

7/874848

Inventors:

Joseph M. Backer - Tenafly NJ
Michael R. Ostrander - Glen Ridge NJ

Assignee:

American Cyanamid Company - Wayne NJ

International Classification:

A61K 3816
A61K 3818

US Classification:

514 2

Abstract:

The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins. Both HBNF and MK possess heparin-binding activity, displace bFGF from high affinity receptors and inhibit growth of endothelial cells.